Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Pancreatic cancer treatment faces challenges due to drug resistance to therapies like dasatinib.
• Dasatinib, a tyrosine kinase inhibitor, shows promise but is limited by intrinsic and acquired resistance.
• Identifying novel therapeutic targets is crucial for improving dasatinib efficacy in pancreatic cancer.

Purpose of the Study:

• To conduct an unbiased genomic screen for functional targets that enhance dasatinib effectiveness in pancreatic cancer.
• To identify genes that exhibit synthetic lethality when combined with dasatinib treatment.
• To explore potential therapeutic strategies for overcoming dasatinib resistance in pancreatic cancer.

Main Methods:

• Utilized a dasatinib-resistant pancreatic cancer cell line (SU8686) for screening.
• Employed a pooled human shRNA library for a genome-wide synthetic lethality screen.
• Applied next-generation sequencing to identify novel synergistic targets.

Main Results:

• Identified several novel genes whose silencing significantly enhanced dasatinib's inhibitory effect on pancreatic cancer cells.
• Discovered that genes involved in epigenetic regulation and the FOXO and hedgehog signaling pathways are key targets.
• Demonstrated that small molecule inhibitors of histone deacetylases or nuclear exporters synergize with dasatinib.

Conclusions:

• The identified novel genes represent potential therapeutic targets for enhancing dasatinib efficacy in pancreatic cancer.
• Targeting epigenetic regulators and specific signaling pathways (FOXO, hedgehog) offers a promising strategy to overcome dasatinib resistance.
• Combination therapies involving dasatinib with histone deacetylase or nuclear exporter inhibitors show significant therapeutic potential for pancreatic cancer.